Drug Trial Radar · NCT05476783
A Long Term Extension Study to Assess the Safety of TB006 in Participants With Alzheimer's Disease
Last checked: Nov 19, 2026Latest source record: May 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
119
Actual
Start
Sep 15, 2022
Primary completion
Nov 17, 2023
Study completion Nov 17, 2023
Sponsor
- Lead sponsor
- TrueBinding, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 27, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label long term extension study for participants with Alzheimer's disease (AD) who have completed Protocol TB006AD2102 (lead-in study) or participants who would have been eligible for the lead-in study but were not enrolled (de novo). The study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of TB006. The total study duration for each participant will be up to 113 weeks.
Conditions
- Alzheimer's Disease
Interventions
TB006Drug
Clear to slightly opalescent, sterile solution for injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events and Serious Adverse EventsTime frame: Up to 61 weeks
- Number of Participants With Clinically Significant Clinical Laboratory Parameter ValuesTime frame: Up to 61 weeks
- Number of Participants With Clinically Significant Vital Sign ValuesTime frame: Up to 61 weeks
- Number of Participants With Clinically Significant 12-Lead Electrocardiogram FindingsTime frame: Up to 61 weeks
- Change From Baseline in Columbia Suicide Severity Rating Scale (C-SSRS)Time frame: Baseline and up to 61 weeks
- Plasma Concentration of TB006Time frame: Pre-dose, and Weeks 1, 5, 9, 13, 17, 21, 25, 45, 73, 101, 113 and ED/EOS up to Week 61
- Number of Participants With Anti-TB006 AntibodiesTime frame: Up to 61 weeks
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
Clinical Trial Site
San Diego, California
Clinical Trial Site
Delray Beach, Florida
Clinical Trial Site
Lady Lake, Florida
Clinical Trial Site
Maitland, Florida
Clinical Trial Site
Miami, Florida
Clinical Trial Site
Miami, Florida
Clinical Trial Site
Miami, Florida
Clinical Trial Site
West Palm Beach, Florida
Clinical Trial Site
Winter Park, Florida
Clinical Trial Site
Winter Park, Florida
Clinical Trial Site
Decatur, Georgia
Clinical Trial Site
Matthews, North Carolina
Clinical Trial Site
Fairfax, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.